Detection apparatus for differential-charged particle mobility analyzer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-027/62
G01N-031/00
A61K-009/127
C07K-014/775
출원번호
US-0537191
(2009-08-06)
등록번호
US-9354200
(2016-05-31)
발명자
/ 주소
Caulfield, Michael P.
출원인 / 주소
QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
대리인 / 주소
Foley & Lardner
인용정보
피인용 횟수 :
0인용 특허 :
30
초록
The present invention provides devices and methods for identification and/or quantitation of particles through detection of fluorescence labeled particles in an apparatus for differential charged particle mobility analysis and fluorescence detection.
대표청구항▼
1. A method for absolute quantitation of a number of lipoprotein particles in a biological sample, said method comprising: a) contacting said sample with a first fluorophore labeled entity capable of integrating into a lipoprotein particle of interest in the sample to generate a first fluorescently
1. A method for absolute quantitation of a number of lipoprotein particles in a biological sample, said method comprising: a) contacting said sample with a first fluorophore labeled entity capable of integrating into a lipoprotein particle of interest in the sample to generate a first fluorescently labeled lipoprotein particle;b) introducing the first fluorescently labeled lipoprotein particles to an apparatus for differential-charged particle mobility analysis and fluorescence detection; andc) quantitating the number of fluorescently labeled lipoprotein particles in the apparatus;wherein said lipoprotein particles are Lipoprotein (a) particles; and said fluorophore labeled entity is an aptamer or antibody capable of specifically binding Apolipoprotein (a). 2. The method of claim 1, wherein said biological sample is selected from the group consisting of whole blood, serum, and plasma. 3. The method of claim 1, wherein said sample comprises one or more lipoprotein particles selected from the group consisting of high density lipoprotein (HDL), low density lipoprotein (LDL), intermediate density lipoprotein (IDL), very low density lipoprotein (VLDL), and oxidized LDL. 4. The method of claim 3, further comprising: d) contacting said sample with a second fluorophore labeled entity prior to introduction into the differential mobility analyzer,wherein said second fluorophore labeled entity comprises fluorophore labeled aptamers or antibodies capable of specifically binding one or more of Apolipoprotein A1 (Apo A1) or Apolipoprotein B (Apo B), and wherein said first and said second fluorophore labeled entities have different fluorescence characteristics. 5. The method of claim 4, further comprising: e) contacting said sample with a third fluorophore labeled entity prior to introduction into the differential mobility analyzer,wherein said third fluorophore labeled entity comprises a fluorophore labeled binding protein capable of specifically binding oxidized LDL, and wherein said first, said second, and said third fluorophore labeled entities have different fluorescence characteristics. 6. The method of claim 1, wherein said first fluorophore labeled entity is a lipophilic fluorophore. 7. The method of claim 6, wherein said lipophilic fluorophore is selected from the group consisting of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate (DiI), 3,3′-dioctadecyloxacarbocynanine perchlorate (DiO), 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocynanine perchlorate (DiD), and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocynanine iodide (DiR), Alexa Fluor 488 (carboxylic acid, succinimidyl ester ‘mixed isomers’), and fluorescein-5-EX, succinimidyl ester. 8. The method of claim 6, wherein the lipophilic fluorophore is 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate (DiI) or Alexa Fluor 488 (carboxylic acid, succinimidyl ester ‘mixed isomers’). 9. The method of claim 1, wherein the first fluorophore labeled entity is a fluorophore labeled lipid. 10. The method of claim 9, wherein said fluorophore labeled lipid is labeled with a lipophilic fluorophore. 11. The method of claim 10, wherein said lipophilic fluorophore is selected from the group consisting of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate (DiI), 3,3′-dioctadecyloxacarbocynanine perchlorate (DiO), 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocynanine perchlorate (DiD), and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocynanine iodide (DiR), Alexa Fluor 488 (carboxylic acid, succinimidyl ester ‘mixed isomers’), and fluorescein-5-EX, succinimidyl ester. 12. The method of claim 11, wherein the lipophilic fluorophore is 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate (DiI) or Alexa Fluor 488 (carboxylic acid, succinimidyl ester ‘mixed isomers’).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (30)
Koren Eugen ; Koscec Mirna, Antibodies to lipoproteins and apolipoproteins and methods of use thereof.
Hairston Peter P. (St. Paul MN) Dorman Frank D. (Golden Valley MN) Sem Gilmore J. (Lauderdale MN) Agarwal Jugal K. (New Brighton MN), Apparatus for measuring particle sizes and velocities.
Griffin Linda ; Albrecht Glenn ; Latham John ; Leung Lawrence ; Vermaas Eric ; Toole John J., Aptamers specific for biomolecules and methods of making.
Kaufman Stanley L. (New Brighton MN) Zarrin Fahimeh (St. Paul MN) Dorman Frank (Minneapolis MN), Electrospray apparatus for producing uniform submicrometer droplets.
Otvos James D. (1827 E. Kenmore Pl. Shorewood WI 53211), Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer.
Zarrin Fahimeh (St. Paul MN) Kaufman Stanley L. (Minneapolis MN) Dorman Frank D. (Golden Valley MN), Method and apparatus for determining concentration of macromolecules and colloids in a liquid sample.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.